Exceptional, Naturally Occurring HIV-1 Control: Insight into a Functional Cure

Overview

Journal Med

Publisher Cell Press

Specialty General Medicine

Date 2024 Jul 16

PMID 39013460

Authors

Maria Salgado

Stephen A Migueles

Xu G Yu

Javier Martinez-Picado

Affiliations

Soon will be listed here.

Abstract

Exceptional elite controllers represent an extremely rare group of people with HIV-1 (PWH) who exhibit spontaneous, high-level control of viral replication below the limits of detection in sensitive clinical monitoring assays and without disease progression in the absence of antiretroviral therapy for prolonged periods, frequently exceeding 25 years. Here, we discuss the different cases that have been reported in the scientific literature, their unique genetic, virological, and immunological characteristics, and their relevance as the best model for the functional cure of HIV-1.

Citing Articles

HIV controllers: hope for a functional cure.

Deng Z, Yan H, Lambotte O, Moog C, Su B Front Immunol. 2025; 16:1540932.

PMID: 40070826 PMC: 11893560. DOI: 10.3389/fimmu.2025.1540932.

References

Lamine A, Caumont-Sarcos A, Chaix M, Saez-Cirion A, Rouzioux C, Delfraissy J . Replication-competent HIV strains infect HIV controllers despite undetectable viremia (ANRS EP36 study). AIDS. 2007; 21(8):1043-5. DOI: 10.1097/QAD.0b013e3280d5a7ac. View

Reynolds M, Weiler A, Weisgrau K, Piaskowski S, Furlott J, Weinfurter J . Macaques vaccinated with live-attenuated SIV control replication of heterologous virus. J Exp Med. 2008; 205(11):2537-50. PMC: 2571929. DOI: 10.1084/jem.20081524. View

Autran B, Descours B, Avettand-Fenoel V, Rouzioux C . Elite controllers as a model of functional cure. Curr Opin HIV AIDS. 2011; 6(3):181-7. DOI: 10.1097/COH.0b013e328345a328. View

Pelak K, Goldstein D, Walley N, Fellay J, Ge D, Shianna K . Host determinants of HIV-1 control in African Americans. J Infect Dis. 2010; 201(8):1141-9. PMC: 2838940. DOI: 10.1086/651382. View

Canoui E, Lecuroux C, Avettand-Fenoel V, Gousset M, Rouzioux C, Saez-Cirion A . A Subset of Extreme Human Immunodeficiency Virus (HIV) Controllers Is Characterized by a Small HIV Blood Reservoir and a Weak T-Cell Activation Level. Open Forum Infect Dis. 2017; 4(2):ofx064. PMC: 5450900. DOI: 10.1093/ofid/ofx064. View

Tilton J, Luskin M, Johnson A, Manion M, Hallahan C, Metcalf J . Changes in paracrine interleukin-2 requirement, CCR7 expression, frequency, and cytokine secretion of human immunodeficiency virus-specific CD4+ T cells are a consequence of antigen load. J Virol. 2006; 81(6):2713-25. PMC: 1865970. DOI: 10.1128/JVI.01830-06. View

Casado C, Galvez C, Pernas M, Tarancon-Diez L, Rodriguez C, Sanchez-Merino V . Permanent control of HIV-1 pathogenesis in exceptional elite controllers: a model of spontaneous cure. Sci Rep. 2020; 10(1):1902. PMC: 7002478. DOI: 10.1038/s41598-020-58696-y. View

Mendoza D, Johnson S, Peterson B, Natarajan V, Salgado M, Dewar R . Comprehensive analysis of unique cases with extraordinary control over HIV replication. Blood. 2012; 119(20):4645-55. PMC: 3367872. DOI: 10.1182/blood-2011-10-381996. View

Dickter J, Aribi A, Cardoso A, Gianella S, Gendzekhadze K, Li S . HIV-1 Remission after Allogeneic Hematopoietic-Cell Transplantation. N Engl J Med. 2024; 390(7):669-671. PMC: 10906479. DOI: 10.1056/NEJMc2312556. View

10.

Cuzin L, Pugliese P, Saune K, Allavena C, Ghosn J, Cottalorda J . Levels of intracellular HIV-DNA in patients with suppressive antiretroviral therapy. AIDS. 2015; 29(13):1665-71. DOI: 10.1097/QAD.0000000000000723. View

11.

Soghoian D, Jessen H, Flanders M, Sierra-Davidson K, Cutler S, Pertel T . HIV-specific cytolytic CD4 T cell responses during acute HIV infection predict disease outcome. Sci Transl Med. 2012; 4(123):123ra25. PMC: 3918726. DOI: 10.1126/scitranslmed.3003165. View

12.

Bailey J, Williams T, Siliciano R, Blankson J . Maintenance of viral suppression in HIV-1-infected HLA-B*57+ elite suppressors despite CTL escape mutations. J Exp Med. 2006; 203(5):1357-69. PMC: 2121215. DOI: 10.1084/jem.20052319. View

13.

Hutter G, Nowak D, Mossner M, Ganepola S, Mussig A, Allers K . Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation. N Engl J Med. 2009; 360(7):692-8. DOI: 10.1056/NEJMoa0802905. View

14.

Hubert J, Burgard M, Dussaix E, Tamalet C, Deveau C, Le Chenadec J . Natural history of serum HIV-1 RNA levels in 330 patients with a known date of infection. The SEROCO Study Group. AIDS. 2000; 14(2):123-31. DOI: 10.1097/00002030-200001280-00007. View

15.

Pernas M, Tarancon-Diez L, Rodriguez-Gallego E, Gomez J, G Prado J, Casado C . Factors Leading to the Loss of Natural Elite Control of HIV-1 Infection. J Virol. 2017; 92(5). PMC: 5809746. DOI: 10.1128/JVI.01805-17. View

16.

Moranguinho I, Valente S . Block-And-Lock: New Horizons for a Cure for HIV-1. Viruses. 2020; 12(12). PMC: 7765451. DOI: 10.3390/v12121443. View

17.

Dalmasso C, Carpentier W, Meyer L, Rouzioux C, Goujard C, Chaix M . Distinct genetic loci control plasma HIV-RNA and cellular HIV-DNA levels in HIV-1 infection: the ANRS Genome Wide Association 01 study. PLoS One. 2008; 3(12):e3907. PMC: 2603319. DOI: 10.1371/journal.pone.0003907. View

18.

Hsu J, Van Besien K, Glesby M, Pahwa S, Coletti A, Warshaw M . HIV-1 remission and possible cure in a woman after haplo-cord blood transplant. Cell. 2023; 186(6):1115-1126.e8. PMC: 10616809. DOI: 10.1016/j.cell.2023.02.030. View

19.

Kiepiela P, Leslie A, Honeyborne I, Ramduth D, Thobakgale C, Chetty S . Dominant influence of HLA-B in mediating the potential co-evolution of HIV and HLA. Nature. 2004; 432(7018):769-75. DOI: 10.1038/nature03113. View

20.

Violari A, Cotton M, Kuhn L, Schramm D, Paximadis M, Loubser S . A child with perinatal HIV infection and long-term sustained virological control following antiretroviral treatment cessation. Nat Commun. 2019; 10(1):412. PMC: 6345921. DOI: 10.1038/s41467-019-08311-0. View